- Home
- TNON vs CARM Comparison
TNON vs CARM Comparison
Compare TNON & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- CARM
- Stock Information
- Founded
- TNON 2012
- CARM 2016
- Country
- TNON United States
- CARM United States
- Employees
- TNON N/A
- CARM N/A
- Industry
- TNON Medical Specialities
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- CARM Health Care
- Exchange
- TNON Nasdaq
- CARM Nasdaq
- Market Cap
- TNON 11.5M
- CARM 12.2M
- IPO Year
- TNON 2022
- CARM N/A
- Fundamental
- Price
- TNON $1.17
- CARM $0.31
- Analyst Decision
- TNON Strong Buy
- CARM Hold
- Analyst Count
- TNON 2
- CARM 5
- Target Price
- TNON $5.50
- CARM $0.90
- AVG Volume (30 Days)
- TNON 269.5K
- CARM 25.7M
- Earning Date
- TNON 11-12-2025
- CARM 11-06-2025
- Dividend Yield
- TNON N/A
- CARM N/A
- EPS Growth
- TNON N/A
- CARM N/A
- EPS
- TNON N/A
- CARM N/A
- Revenue
- TNON $2,947,000.00
- CARM $10,767,000.00
- Revenue This Year
- TNON $43.52
- CARM N/A
- Revenue Next Year
- TNON $82.14
- CARM N/A
- P/E Ratio
- TNON N/A
- CARM N/A
- Revenue Growth
- TNON N/A
- CARM N/A
- 52 Week Low
- TNON $0.85
- CARM $0.14
- 52 Week High
- TNON $7.51
- CARM $1.27
- Technical
- Relative Strength Index (RSI)
- TNON 44.55
- CARM 47.53
- Support Level
- TNON $1.13
- CARM $0.34
- Resistance Level
- TNON $1.26
- CARM $0.39
- Average True Range (ATR)
- TNON 0.07
- CARM 0.06
- MACD
- TNON -0.01
- CARM 0.00
- Stochastic Oscillator
- TNON 26.09
- CARM 29.91
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.